| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 2003 | Volume 139 Issue 2 | Pages 123-136
While performance of percutaneous coronary intervention (PCI) remains the domain of specialized cardiologists, patients undergoing PCI are cared for by noninvasive cardiologists, internists, and primary care physicians. Therefore, patient care is optimized when the entire patient care team understands procedural risks and complications as well as optimum patient management before, during, and after PCI.
Before PCI, patients with contrast dye allergies should be identified and pretreated with steroids and an H1-blocker. Hydration should be initiated and maintained before and after the procedure to minimize the risks for contrast nephropathy. Periprocedure, patients should be monitored clinically for evidence of ischemia. In patients with significant groin, flank, abdominal, or back pain, as well as those with decrease in hematocrit or unexplained hypotension, the diagnosis of groin or retroperitoneal hematoma should be considered and promptly evaluated. Groin tenderness, pulsatile mass, or bruit should prompt evaluation for possible femoral pseudoaneurysm or arteriovenous fistulae. After the procedure, all patients treated with coronary stents should receive aspirin plus clopidogrel. Patients who develop typical anginal symptoms between the 1st and 6th to 8th months after PCI are likely to have restenosis and can be evaluated by an imaging study or repeated catheterization.
Author and Article Information
From Baylor College of Medicine, Houston, Texas; St. Louis University, St. Louis, Missouri; Mayo Clinic, Rochester, Minnesota; Beth Israel Medical Center, New York, New York; Rush Medical College, Chicago, Illinois; The Lindner Research Center and Ohio Heart Health Center, Cincinnati, Ohio; Evanston Northwestern Healthcare, Evanston, Illinois; and Boston University School of Medicine, Boston, Massachusetts.
Potential Financial Conflicts of Interest:Consultancies: G.N. Levine (Aventis, Schering-Plough, Merck, Pfizer, The Medicines Company), P.B. Berger (BMS/Sanofi, Aventis), T.A. Sanborn (Davax, Boston Scientific, Genvac, Ethicon); Honoraria: G.N. Levine (Aventis, Schering-Plough, Merck, Pfizer, The Medicines Company), P.B. Berger (BMS/Sanofi, Aventis); Grants received: P.B. Berger (BMS/Sanofi, Merck, Cordis Millennium), T.A. Sanborn (X-SITE Medical).
Requests for Single Reprints: Glenn N. Levine, MD, Section of Cardiology 3C-330, Houston Veterans Affairs Medical Center (111-B), 2002 Holcombe Boulevard, Houston, TX 77030; e-mail, glevine{at}bcm.tmc.edu.
Current Author Addresses: Dr. Levine: Section of Cardiology 3C-330, Houston Veterans Affairs Medical Center (111-B), 2002 Holcombe Boulevard, Houston, TX 77030.
Dr. Kern: St. Louis University, 3635 Vista Avenue, St. Louis, MO 63110.
Dr. Berger: Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Dr. Brown: Beth Israel Medical Center, 16th Street at First Avenue, New York, NY 10003.
Dr. Klein: Rush Heart Institute, 1653 West Congress, Chicago, IL 60612.
Dr. Kereiakes: Lindner Research Center, Ohio Heart Health Center, Suite 424, 2123 Auburn Avenue, Cincinnati, OH 45219.
Dr. Sanborn: Evanston Northwestern Healthcare, 2550 Ridge Avenue, Evanston, IL 60201.
Dr. Jacobs: Boston Medical Center, 88 East Newton Street, Boston, MA 02118. REVIEW
Management of Patients Undergoing Percutaneous Coronary Revascularization
![]()
Related articles in Annals:
This article has been cited by other articles:
![]() |
T. Y. Wang, E. D. Peterson, D. Dai, H. V. Anderson, S. V. Rao, R. G. Brindis, M. T. Roe, and on behalf of the National Cardiovascular Data Regi Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report From the National Cardiovascular Data Registry (NCDR) J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2068 - 2074. [Full Text] [PDF] |
||||
![]() |
U. C. Rangasetty and C. Y. Lui Fractional flow reserve-guided intervention of angiographically nonsignificant coronary stenoses. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1123 - 1123. [Full Text] [PDF] |
||||
![]() |
C. L. Grines, R. O. Bonow, D. E. Casey Jr, T. J. Gardner, P. B. Lockhart, D. J. Moliterno, P. O'Gara, and P. Whitlow Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Dent Assoc, May 1, 2007; 138(5): 652 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Grines, R. O. Bonow, D. E. Casey Jr, T. J. Gardner, P. B. Lockhart, D. J. Moliterno, P. O'Gara, and P. Whitlow Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians J. Am. Coll. Cardiol., February 13, 2007; 49(6): 734 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Grines, R. O. Bonow, D. E. Casey Jr, T. J. Gardner, P. B. Lockhart, D. J. Moliterno, P. O'Gara, and P. Whitlow Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians Circulation, February 13, 2007; 115(6): 813 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Balian, M. Galli, C. Marcassa, G. Cecchin, M. Child, F. Barlocco, E. Petrucci, G. Filippini, R. Michi, and M. Onofri Intracoronary ST-Segment Shift Soon After Elective Percutaneous Coronary Intervention Accurately Predicts Periprocedural Myocardial Injury Circulation, October 31, 2006; 114(18): 1948 - 1954. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone and H. D. Aronow Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy Mayo Clin. Proc., May 1, 2006; 81(5): 641 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Nawarskas and L. A. Osborn Paclitaxel-eluting stents in coronary artery disease Am. J. Health Syst. Pharm., November 1, 2005; 62(21): 2241 - 2251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe, E. Braunwald, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study JAMA, September 14, 2005; 294(10): 1224 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, et al. ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction--executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J. Am. Coll. Cardiol., August 4, 2004; 44(3): 671 - 719. [Full Text] [PDF] |
||||
![]() |
E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, G. A. Lamas, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation, August 3, 2004; 110(5): 588 - 636. [Full Text] [PDF] |
||||
![]() |
B. K. Nallamothu and E. R. Bates Periprocedural myocardial infarction and mortality: Causality versus association J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1412 - 1414. [Full Text] [PDF] |
||||